To validate, in a multi-institution review, the safety, accuracy and reliability of renal tumour biopsy (RTB) and its role in decreasing unnecessary treatment.
Introduction
Over the last decade, there has been an increase in the incidence of small renal masses (SRMs) as a result of the greater use of abdominal imaging [1] . Although the majority of SRMs are malignant, between 20 and 30% are benign [2] . There is currently no imaging method that can reliably identify the histology of lipid-poor solid lesions [3] . Renal tumour biopsy (RTB) has been proposed as a means by which to characterize the pre-treatment histology of SRMs, ultimately leading to a reduction in overtreatment [4] . Despite being safe, reliable and accurate, RTBs have not been widely adopted by the urological community, and the vast majority of patients diagnosed with an SRM continue to be managed with upfront surgery or thermal ablation [5] . One of the concerns regarding RTB is that its benefits have not been validated outside of single-institution series [1, 4, [6] [7] [8] ; therefore, whether or not their diagnostic rates, reliability and safety are reproducible across several institutions is yet to be proven.
In the present study, we describe the diagnostic rate of RTB and how this improved over time, assess the factors associated with obtaining a diagnostic biopsy and assess its concordance with surgical pathology. Additionally, we studied the uptake of RTB over time.
Material and Methods

Patient Selection
This was an institutional review board-approved retrospective study. Patients who underwent RTB for a radiographically indeterminate SRM between 1 January 2011 and 31 May 2015 were identified through the prospectively maintained Canadian Kidney Cancer information system (CKCis). The CKCis is an access-restricted web-based clinical registry where information on patients who were managed for kidney cancer, including SRMs, is collected from 15 participating centres across Canada [9] . Of these centres, 12 had reported at least one RTB during the study period.
Overall, a total of 1,018 percutaneous RTBs were performed during the study period. Of these, 525 RTBs were excluded because the lesion measured ≥4 cm and 79 were excluded because they were performed to exclude a recurrence in the ablation or surgical bed or were performed at the time of radiofrequency ablation. Another 26 RTBs were excluded because they were performed to confirm the diagnosis of the initial biopsy (n = 22) or because of incomplete outcome data (n = 4). The final cohort therefore comprised 388 biopsies of 373 SRMs (Fig. 1) .
Data Analysed
The patient demographic characteristics (age at diagnosis and gender) as well as the lesion (laterality, location, size, exophytic appearance, histology, Fuhrman grade) and procedural characteristics (year of biopsy, annual RTB volume per institution, peri-procedural morbidity and type of subsequent intervention) were abstracted from the database. The lesion size was defined as the maximum tumour dimension at the time of diagnosis. The tumour histology was classified according to the WHO system [10] . Tumours for which histological subtype was not reported were defined as RCC, unspecified. Fuhrman grades were abstracted for clear-cell RCC (ccRCC) histology only. If two grades were assigned to the same specimen, only the highest grade was recorded. A two-tier grading system was also used to categorize grades. Grades 1 and 2 were defined as low grade; 3 and 4 as high grade [11, 12] . In cases where a definitive diagnosis could not be established after RTB, or in cases where non-renal or unremarkable parenchymal tissue was biopsied, the outcome of the RTB was recorded to be non-diagnostic.
All RTBs were performed by one of the 12 centres' interventional radiologists. The size of the biopsy needle and the number of cores taken at the time of RTB were left to the discretion of the interventional radiologists. All pathological specimens were processed according to standard pathological procedures at each institution. Additional tests were carried out at the discretion of the pathologists. No central pathology review was performed.
Objectives
The primary objectives of the study were to present the diagnostic and non-diagnostic rates of RTB and to identify the factors associated with achieving a diagnostic biopsy at the time of the initial RTB. Secondary objectives were to determine whether the proportion of SRMs undergoing biopsy before surgical extirpation increased over time, to ascertain the concordance rate with regard to tumour histology and grade between the RTB and surgical pathology, to assess the safety of RTB and to determine how RTB influenced SRM management.
Statistical Analysis
Continuous variables were reported as medians and interquartile ranges (IQRs), while categorical variables were described with proportions. The cohort baseline characteristics were compared using the Wilcoxon rank-sum test for continuous variables and the chi-squared test for proportions for categorical variables. Univariable regression models were generated to test the hypothesis of an association between patient (age at diagnosis and gender), lesion (laterality, location, size, exophytic appearance), procedure-related characteristics (year of biopsy, annual RTB volume performed by the centre) and the odds of obtaining a diagnostic biopsy at the time of the initial RTB. Given the outcome of the univariable analysis outcomes, multivariable analyses were not conducted. The odds ratios are presented with their 95% CIs. The Cochran-Armitage test for trend was used to test whether the diagnostic rates and the use of the RTBs increased over the years. Where applicable, proportions were used to report the histological and Fuhrman grade concordance between RTB pathology and definitive surgical pathology. Statistical analyses were conducted in the R statistical environment, version 3.2.3 (R core team, Vienna, Austria) [13] . All tests were two-sided and P values <0.05 were considered statistically significant.
Results
A total of 373 biopsied SRMs in 351 patients were included in the analysis (Fig. 1) . The baseline patient, tumour and procedure characteristics are shown in Table 1 . Of these biopsied masses, the initial RTB was diagnostic in 87% (n = 326) of cases, of which 18% (n = 59) were found to be benign. Of the non-diagnostic RTBs (n = 47), 15 underwent a repeat biopsy that was diagnostic in 12 (80%), including three with benign histology. When the results of the initial and repeat biopsy were combined, a diagnosis was obtained in 91% (n = 338) of SRMs. Overall, 18% (n = 62) of these masses were found to be benign, whereas the majority of malignant tumours were found to be ccRCC of low Fuhrman grade ( Table 2 ). Only two patients (0.6%) developed an adverse event after RTB, both of which were haemorrhagic, with one requiring angio-embolization (Clavien-Dindo classification grades I and IIIa, respectively). No needle tract seeding was reported. On univariable analysis, the only factor found to be associated with the biopsy outcome was the tumour size (odds ratio 1.71, 95% CI: 1.07-2.73, for each additional cm). None of the other evaluated characteristics were found to be significant (Table 3) .
Although the diagnostic rates improved from 83% in 2011 to 87% in 2014-2015, the difference was not statistically significant (P = 0.75). Moreover, there was an increase in the use of RTB during the study period, as a greater proportion of patients who underwent surgery for a cT1a lesion underwent a RTB beforehand. This proportion increased significantly, from 18% in 2011 to 25% in 2014-2015 (P = 0.03; Fig. 2 ).
After RTB, the majority of masses were surgically treated (n = 188, 50%) or ablated (n = 40, 11%). Of the patients considered to have been treated, 21 were treated after 12 months (17 in the nephrectomy group; four in the radiofrequency ablation group); therefore, these patients were probably initially managed conservatively. The remaining 145 SRMs (39%) were managed conservatively. Their histologies are shown in Table S1 . Of the SRMs managed surgically, the pathologies of both the RTB and surgery were available in 176 cases (94%). RTB was found to be concordant with surgical histology in 88% (154/176) of cases (Table 4A ). More specifically, RTB correctly identified ccRCC, papillary RCC and chromophobe RCC in 93% (102/110), 86% (37/43) and 88% (7/8) of cases, respectively.
When assessing Fuhrman grades for lesions identified to be ccRCC, pathologists were able to assign a grade on RTB in 74% (n = 85/116) of cases. Of the cases with assigned grades on both RTB and surgery, the RTB grades were concordant with the surgical ones in 58% (49/85) of cases. When grades were pooled into low (G1-G2) and high (G3-G4) grades, the concordance was much higher (81% ; Table 4B ); however, all 16 discordant cases were under-graded on RTB when compared with surgical pathology.
Discussion
Although recent evidence has in large part answered the concerns regarding the safety, accuracy and reliability of pretreatment biopsy [4, 14] , critics have continued to argue that results were perhaps not generalizable; the results of the present large multi-institution retrospective study have largely addressed this concern.
We have provided evidence supporting the high diagnostic yield of RTBs by showing that they led to a diagnosis after the initial biopsy in 87% of cases. Importantly, physicians should remember that a non-diagnostic biopsy does not exclude the presence of cancer, and patients and/or physicians should not be falsely reassured by this result. Among patients undergoing a repeat biopsy after an initially non-diagnostic one, a diagnosis was obtained in 80% (12/15) of cases, of which nine were malignant. Thus, when the outcomes from the first and second biopsy were combined, RTBs led to a diagnosis in 91% of SRMs. These results are consistent with previously reported diagnostic rates from single-institution series and are similar to the rates observed in a recent meta-analysis presented by Marconi et al. which reported a diagnostic rate of 92% (IQR 81-97%) [1, 3, 4, 7, 8, [14] [15] [16] [17] . Similar rates (86%) were also reported in a large systematic review by Patel et al. [18] .
The present results also confirm previous reports that a higher diagnostic yield was achieved in larger tumours [4, 8] ; however, we were not able to confirm that biopsies performed for exophytic lesions were more likely to be diagnostic than biopsies performed for endophytic ones, as recently suggested by the group from the University of Toronto [4] ; therefore, this association remains to be validated.
One of the most often quoted deterrents from RTBs, is its notoriously low concordance rate with surgical pathology [19, 20] ; however, the experience from the University of Toronto has provided evidence that the concordance rates were much higher than initially thought, with a concordance rate of 93% for histology and 94% for grade (when pooled into low and high grade) [4] . Similar findings were observed in the meta-analysis by Marconi et al. [14] , which showed concordance rates of 90% (IQR 84-94%) and 62%, for histology and grade, respectively. When pooled into the twotier grading system, much better rates were reported in the meta-analysis (87%, IQR 71-98%). Nevertheless, as highlighted by the present results, one has to remember that RTBs have a tendency to undergrade when compared with surgical pathology. This shortcoming of RTB is especially of importance to programmes where initial active surveillance is offered to patients.
This study also confirms the safety of RTBs outside of the boundaries of single-institution series. Rates similar to those in the present study have been described in the literature, with major complications reported in <1% of cases [4, 14, 21] . Moreover, although needle tract seeding remains a possibility, none of the included patients had experienced such an event, and this risk has seldom been reported after 2001 [22] . One of the potential explanations for this is the increasing use of a coaxial sheath that decreases the direct contact of the needle with the surrounding tissue. Unfortunately, the rate of their utilization in the present series is unknown as these data were not captured by the registry. The theoretical risk of seeding should therefore not be a deterrent to biopsy.
Another key finding from the present results was that, contrary to previous studies [5] , we have demonstrated evidence of an increase in the acceptance of RTB as an initial step in the management of patients diagnosed with an SRM; however, despite this growing acceptance, the utilization rate of RTB remains low because only a quarter of patients who underwent surgery for an SRM in 2014-2015 were biopsied beforehand.
Regardless of its encouraging findings, the present study has several limitations. First, the data are based on a prospectively maintained multi-institution registry that was originally intended for kidney cancer, therefore, there is a potential bias toward omitting non-diagnostic or benign RTB results, thus potentially biasing the diagnostic rates and proportion of malignant lesions. Additionally, not all patients diagnosed with an SRM in the study period were biopsied and, as a result, a selection bias may be present. The true impact of these limitations is unknown. Likewise, although the CKCis database is prospectively maintained, peri-procedural complications are retrospectively captured and therefore, may have been under-reported. Furthermore, although considerable detail was available in the CKCis for analysis, some patient, tumour and procedural characteristics were missing or were not available. As a result, it is possible that non-captured or poorly captured characteristics may have influenced our ability to identify factors associated with the odds of achieving a diagnostic biopsy. Lastly, after RTB, most of the identified benign SRMs and a significant proportion of the malignant ones were not surgically excised. Without surgical confirmation, it is possible that some of the SRMs (especially the oncocytic renal neoplasm ones) may have been misclassified as being benign or malignant [23] . Even though misclassification is a possibility, there is early evidence to suggest that these tumours can be managed conservatively, at least in the short term [24] . It is our opinion, therefore, that even benign histology on RTB should be followed by serial imaging, usually every 3-6 months for the first year and then yearly, if growth is absent or slow. A similar follow-up protocol has also been suggested by other authors [25] . Additionally, physicians following these lesions should remember that growth is not necessarily a sign of malignancy and thus, this should not be used as the sole indication to treat SRMs [24] . Nevertheless, it has been our practice to repeat a biopsy among fast-growing lesions (>0.5 cm/year) and it is our opinion that any SRMs managed conservatively, even those identified as being benign on RTB, should be followed with routine imaging.
Although it has some limitations, the present study provides further evidence of the safety, reliability and accuracy of RTB outside of well-designed single-institution series. It also supports RTB as a tool with which to decrease overtreatment rates. Moreover, as active surveillance is being increasingly recognized as a valid treatment option to manage SRMs [26] , RTBs may become increasingly helpful in some patients as method of reducing treatment-associated anxiety and to guide treatment [25, 27] .
Given the current evidence, it seems more and more difficult to continue to offer upfront treatment to patients diagnosed incidentally with an SRM as RTB offers important information with limited morbidity and facilitates more personalization of care. At the very least, RTB should be discussed with patients in whom a definitive treatment is being considered and who are willing to accept the known limitations of RTB [28] .
In conclusion, the present study provides further evidence of the potential benefits of RTB outside of a single-institution series. With the increasing use of imaging, an increasing number of SRMs are being diagnosed. Despite the evidence supporting the role of RTB in the management of SRMs, the vast majority of SRMs are still being treated with upfront definitive treatment, which results in considerable overtreatment. Consequently, for patients in whom a definitive treatment is being considered, we believe that it is now time to reconsider the current treatment paradigm of SRM as a way to reduce overtreatment, the cost of treatment and, more importantly, limit treatment-related morbidity. Given the current evidence, RTBs may be a helpful tool with which to triage patients diagnosed with an incidental SRM in order to guide appropriate management.
